Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib

Show other versions (1)

In the past decade, molecular-targeted drugs have been focused upon for the treatment of cancer. In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor became available in Japan for the treatment of non-small cell lung cancer (NSCLC). Over 80% of selected patients,...

Full description

Bibliographic Details
Main Authors: Takuya Araki, Hideaki Yashima, Kimihiro Shimizu, Tohru Aomori, Tadahiro Hashita, Kyoichi Kaira, Tomonori Nakamura, Koujirou Yamamoto
Format: Article
Language:English
Published: SAGE Publishing 2012-01-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.4137/CMO.S7340

Internet

https://doi.org/10.4137/CMO.S7340

Similar Items